Cellebrite DI Ltd. officer David Gee filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 5,673 ordinary shares with an approximate date of sale of November 23, 2026.

Key Highlights

  • Proposed sale: David Gee, an officer of Cellebrite DI Ltd., intends to sell 5,673 ordinary shares (par value NIS 0.00001) with an aggregate market value of $72,047.10.
  • Source of shares: The 5,673 shares were acquired on November 20, 2026, through restricted share units vested under an issuer S-8 registered plan, with compensation as the nature of payment.
  • Sell-to-cover arrangement: According to the filing, the sale is pursuant to "a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only."
  • Prior three-month sales: Gee sold 230 shares on August 12, 2026, for gross proceeds of $3,695.59; 2,198 shares on August 21, 2026, for $24,709.03; and 4,323 shares on August 24, 2026, for $49,111.44.
  • Shares outstanding: The filing states 251,341,060 ordinary shares outstanding at the time of the notice.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is listed as the broker for the proposed sale.

David Gee's Proposed RSU Vesting Sale at Cellebrite DI

Cellebrite DI Ltd. (NASDAQ:CLBT), an Israel-based company, is the subject of a Form 144 notice filed November 10, 2026, by David Gee, identified in the filing as an officer of the issuer. The notice covers a proposed sale of 5,673 ordinary shares on or around November 23, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

According to the filing, the shares were acquired on November 20, 2026, directly from Cellebrite DI Ltd. via restricted share units vested under an S-8 registered plan, with compensation listed as the nature of payment. The aggregate market value of the proposed sale is listed as $72,047.10. The filing states the sale is mandatory and non-discretionary, intended solely to cover income tax liabilities arising from the vesting of restricted share unit awards.

The filing also discloses three sales by Gee in the prior three months: 230 shares sold on August 12, 2026, for $3,695.59; 2,198 shares sold on August 21, 2026, for $24,709.03; and 4,323 shares sold on August 24, 2026, for $49,111.44. The total shares outstanding are listed as 251,341,060. The notice is dated November 10, 2026, and was signed by David Gee.

What Was Disclosed

Cellebrite DI Ltd. officer David Gee filed a Form 144 on November 10, 2026, disclosing a proposed sale of 5,673 ordinary shares on November 23, 2026, acquired via RSU vesting, with the stated purpose of covering income tax liabilities through a mandatory sell-to-cover arrangement.